StockPreacher.com: ACAD reports net loss of $8.7M for fourth-quarter of 2009

Mar 17 2010

StockPreacher.com announces an investment report featuring ACADIA Pharmaceuticals Inc (Nasdaq:ACAD). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/ACAD

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/StockPreacher

ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis. In addition, the Company has a product candidate in phase II for chronic pain and a product candidate in phase I for glaucoma, both in collaboration with Allergan Inc., and ACP-106 in IND-track development. The Company's product candidates include pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark. 

Message Board Search for ACAD: http://www.boardcentral.com/boards/ACAD

In the report, the analyst notes:

"ACAD reported a net loss of $8.7 million, or $0.23 per common share, for the fourth quarter of 2009 compared to a net loss of $14.0 million, or $0.38 per common share, for the fourth quarter of 2008. The net loss for the fourth quarter of 2009 included charges of $1.3 million in connection with ACAD's restructuring announced in October. 

"Pimavanserin is a small molecule product candidate that the Company discovered and advanced to phase III development as a treatment for patients with Parkinson's disease psychosis (PDP). Pimavanserin can be taken orally and blocks the activity of the 5-HT2A receptor, a key serotonin receptor that plays an important role in the treatment of various psychiatric disorders."